Player FMアプリでオフラインにしPlayer FMう!
Advanced Antibody Discovery Platform Generates COVID-19 Antibody Therapy with Ian Chan Abpro
Manage episode 282055644 series 99915
Ian Chan, CEO, Abpro is developing a drug which is a COVID-19 neutralizing antibody that has demonstrated strong binding affinity for COVID-19 in a Phase 2/3 global trial. Using the Diverse Immune Platform, an advanced antibody discovery platform, Abpro is drawing on years of successful work developing neutralizing monoclonal antibody therapies for treating traditionally difficult to access cancers, eye disease and autoimmune diseases. In addition to vaccines, COVID-19 therapeutics are essential for keeping the disease from progressing particularly for those most at risk.
@abpro #COVID19 #antibodytherapies #monoclonalantibodies
1725 つのエピソード
Manage episode 282055644 series 99915
Ian Chan, CEO, Abpro is developing a drug which is a COVID-19 neutralizing antibody that has demonstrated strong binding affinity for COVID-19 in a Phase 2/3 global trial. Using the Diverse Immune Platform, an advanced antibody discovery platform, Abpro is drawing on years of successful work developing neutralizing monoclonal antibody therapies for treating traditionally difficult to access cancers, eye disease and autoimmune diseases. In addition to vaccines, COVID-19 therapeutics are essential for keeping the disease from progressing particularly for those most at risk.
@abpro #COVID19 #antibodytherapies #monoclonalantibodies
1725 つのエピソード
Alle afleveringen
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。